Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug428 | Azithromycin Tablets Wiki | 0.71 |
| drug1795 | Hydroxychloroquine Sulfate Wiki | 0.29 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a clinical trial to evaluate the safety and immunogenicity of a recombinant adenovirus 5 vectored COVID-19 vaccine (Ad5-nCoV) with two doses and with different adminstration routes in healthy adults aged 18 years and older.
Description: The occurrence of AE in all groups within 0-7 days after each vaccination;
Measure: Incidence of the AE in all groups Time: 0-7 days after each vaccinationDescription: Seroconversion rate the IgG antibody against SARS-CoV-2 measured on Day 28 after last vaccination
Measure: Seroconversion rate of the IgG antibody against SARS-CoV-2 Time: Day 28 after last vaccinationDescription: Geomean titers of the IgG antibody against SARS-CoV-2 measured on Day 28 after last vaccination
Measure: Geomean titers of the IgG antibody against SARS-CoV-2 Time: Day 28 after last vaccinationDescription: Seroconversion rate of the neutralizing antibody against SARS-CoV-2 measured on Day 28 after last vaccination
Measure: Seroconversion rate of the neutralizing antibody against SARS-CoV-2 Time: Day 28 after last vaccinationDescription: Geomean titers of the neutralizing antibody against SARS-CoV-2 measured on Day 28 after last vaccination
Measure: Geomean titers of the neutralizing antibody against SARS-CoV-2 Time: Day 28 after last vaccinationDescription: The occurrence of AE in all groups within 0-30 minutes and 0-28 days after each vaccination.
Measure: Incidence of the AE in all groups Time: 0-30 minutes, 0-28 days after each vaccinationDescription: The occurrence of Serious adverse events (SAE) in all groups within 6 months after the final vaccination.
Measure: Incidence of Serious adverse events (SAE) in all groups Time: 6 months after the final vaccinationDescription: Geomean titers of the IgG antibody against SARS-CoV-2 measured on Day 0, 14, 28 and 56 after first vaccination and on Day 14 and Day168 after last vaccination.
Measure: Geomean titers of the IgG antibody against SARS-CoV-2 Time: Day 0, 14, 28 and 56 after first vaccination and Day 14 and Day168 after last vaccination.Description: Seroconversion rate of the IgG antibody against SARS-CoV-2 measured on Day 0, 14, 28 and 56 after first vaccination and on Day 14 and Day168 after last vaccination.
Measure: Seroconversion rate of the IgG antibody against SARS-CoV-2 Time: Day 0, 14, 28 and 56 after first vaccination and Day 14 and Day168 after last vaccination.Description: Geomean titers of the neutralizing antibody against SARS-CoV-2 measured on Day 0, 14, 28 and 56 after first vaccination and on Day 14 and Day168 after last vaccination.
Measure: Geomean titers of the neutralizing antibody against SARS-CoV-2 Time: Day 0, 14, 28 and 56 after first vaccination and Day 14 and Day168 after last vaccination.Description: Seroconversion rate of the neutralizing antibody against SARS-CoV-2 measured on Day 0, Day14, Day 28 or Day 56 after first vaccination and on day 14, day 28 and day168 after last vaccination.
Measure: Seroconversion rate of the neutralizing antibody against SARS-CoV-2 Time: Day 0, 14, 28 and 56 after first vaccination and on Day 14 and Day168 after last vaccination.Description: The positive rate of IFN-γ stimulated by S protein overlapping peptide library detected by ELISpot on Day 0 and Day 14 after each vaccination
Measure: Cellular immune response by ELISpot Time: Day 0 and Day 14 after each vaccinationDescription: Geomean titers of neutralizing antibody response to Ad5-vector on Day 0, 14 and 28 after each vaccination.
Measure: Geomean titers of neutralizing antibody response to Ad5-vector Time: Day 0, 14 and 28 after each vaccination.Description: The positive rate of the specific cytokines expressed by CD4+ and CD8+ T lymphocytes stimulated by S protein overlapping peptide library detected by intracellular cytokine staining on Day 0 and Day 14 after each vaccination
Measure: Cellular immune response by ICS Time: Day 0 and Day 14 after each vaccinationDescription: Geomean titers of the IgA antibody against SARS-CoV-2 on Day 0, 14 and 28 after each vaccination.
Measure: Geomean titers of the IgA antibody against SARS-CoV-2 Time: Day 0, 14 and 28 after each vaccinationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports